
    
      This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 2
      (Week 0), subjects meeting all entry criteria will be randomized to one of two treatment
      sequences: placebo or P-OM3 for the first 6 week phase followed by the study product they did
      not receive during the first phase (P-OM3 or placebo) for the second 6 weeks.
    
  